Nonvascular retinal imaging markers of preclinical Alzheimer's disease

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 4, Issue , 2016, Pages 169-178

  Snyder, Peter J ^a,b   Johnson, Lenworth N ^a,b   Lim, Yen Ying ^c   Santos, Cláudia Y ^b,d   Alber, Jessica ^a,b   Maruff, Paul ^c,e   Fernández, Brian ^f  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF RHODE ISLAND   (United States)

^e Cogstate Ltd ^*  (Australia)

^f Heidelberg Engineering   (United States)

Author keywords

Acetylcholine; Alzheimer's disease; Biomarkers; Cholinergic hypothesis; Inner plexiform layer; OCT; Optical Coherence Tomography; Preclinical AD; Retina

Indexed keywords

ACETYLCHOLINE; AMYLOID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY TEST; NEOCORTICAL TISSUE; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PROTEIN AGGREGATION; RETINA; RETINA EXAMINATION; RETINAL INNER PLEXIFORM LAYER; RETINAL NERVE FIBER LAYER THICKNESS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SURFACE AREA; TREND STUDY; WORKING MEMORY;

EID: 84992212891     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2016.09.001     Document Type: Article

References (57)

1. [1] Au, R., Piers, R.J., Lancashire, L., Back to the future: Alzheimer's disease heterogeneity revisited. Alzheimers Dement (Amst) 1 (2015), 368–370.
2. [2] McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute of Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7 (2011), 263–269.
3. [3] Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., et al. Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12 (2013), 357–367.
4. [4] Uchida, K., Shan, L., Suzuki, H., Tabuse, Y., Nishimura, Y., Hirokawa, Y., et al. Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline. Alzheimers Dement (Amst) 1 (2015), 270–280.
5. [5] Ashton, N.J., Kiddle, S.J., Graf, J., Ward, M., Baird, A.L., Hye, A., et al. Blood protein predictors of brain amyloid for enrichment in clinical trials?. Alzheimers Dement (Amst) 1 (2015), 48–60.
6. [6] Yeo, J.M., Waddell, B., Khan, Z., Pal, S., A systematic review and meta-analysis of 18 F-labeled amyloid imaging in Alzheimer's disease. Alzheimers Dement (Amst) 1 (2015), 5–13.
7. [7] Doraiswamy, P.M., Sperling, R.A., Johnson, K., Reiman, E.M., Wong, T.Z., Sabbagh, N., et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: A prospective multicenter study. Mol Psychiatry 19 (2014), 1044–1051.
8. [8] Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Ward, A., Huijbers, W., et al. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer's disease. Neurology 82 (2014), 1760–1767.
9. [9] Lim, Y.Y., Ellis, K.A., Pietrzak, R.H., Ames, D., Darby, D., Harrington, K., et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 79 (2012), 1645–1652.
10. [10] Small, G.W., Siddarth, P., Kepe, V., Ercoli, L.M., Burggren, A.C., Bookheimer, S.Y., et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 69 (2012), 215–222.
11. [11] Buckley, R., Saling, M.M., Ames, D., Rowe, C.C., Lautenschlager, N.T., Macaulay, S.L., et al. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age. Int Psychogeriatr 25 (2013), 1307–1315.
12. [12] Fyock, C.A., Hampstead, B.M., Comparing the relationship between subjective memory complaints, objective memory performance, and medial temporal lobe volumes in patients with mild cognitive impairment. Alzheimers Dement (Amst) 1 (2015), 242–248.
13. [13] Lim, Y.Y., Maruff, P., Getter, C., Snyder, P.J., Disclosure of PET Amyloid Imaging Results: A Preliminary Study of Safety and Tolerability. Alzheimers Dement 12 (2016), 454–458.
14. [14] Lim, Y.Y., Maruff, P., Schindler, R., Ott, B.R., Salloway, S., Yoo, D.C., et al. Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease. Neurobiol Aging 36 (2015), 2709–2715.
15. [15] Danesh-Meyer, H.V., Birch, H., Ku, J.Y., Carroll, S., Gamble, G., Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology 67 (2006), 1852–1854.
16. [16] Iseri, P.K., Altina, O., Tokay, T., Yuskel, N., Relationship between cognitive impairment and retinal morphological and visual abnormalities in Alzheimer disease. J Neuroophthamol 26 (2006), 18–24.
17. [17] Paquet, C., Boissonnot, M., Roger, F., Dighiero, P., Gil, R., Hugon, J., Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 420 (2007), 97–99.
18. [18] Thomson, K.L., Yeo, J.M., Waddell, B., Cameron, J.R., Pal, S., A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. Alzheimers Dement (Amst) 1 (2005), 136–143.
19. [19] Berisha, F., Feke, G., Trempe, C., Wallace McMeel, J., Schepens, C., Retinal abnormalities in early Alzheimer's disease. Invest Ophthamol Vis Sci 48 (2007), 2285–2289.
20. [20] Ohno-Matsui, K., Parallel findings in age-related macular degeneration and Alzheimer's disease. Prog Retin Eye Res 30 (2011), 217–238.
21. [21] Howlett, D.R., Bate, S.T., Collier, S., Lawman, S., Chapman, T., Ashmeade, T., et al. Characterisation of amyloid-induced inflammatory responses in the rat retina. Exp Brain Res 214 (2011), 185–197.
22. [22] Keenan, T.D., Goldacre, R., Goldacre, M.J., Associations between age-related macular degeneration, Alzheimer disease, and dementia record linkage study of hospital admissions. JAMA Ophthalmol 132 (2014), 63–68.
23. [23] Xu, H., Chen, M., Forrester, J.V., Para-inflammation in the aging retina. Prog Retin Eye Res 28 (2009), 348–368.
24. th Annual Clinical Trials in Alzheimer's Disease (CTAD) Conference; November, 2015; Barcelona, Spain. J Prev Alzheimers Dis, 2, 2015, 368.
25. [25] Dentchev, T., Milam, A.H., Lee, V.M., Trojanowski, J.Q., Dunaief, J.L., Amyloid-β is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 9 (2003), 184–190.
26. [26] Isas, J.M., Luibl, V., Johnson, L.V., Kayed, R., Wetzel, R., Glabe, G., et al. Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthamol Vis Sci 51 (2010), 1304–1310.
27. [27] Snyder, P.J., Lim, Y.Y., Schindler, R., Ott, B.R., Salloway, S., Daiello, L., et al. Microdosing of Scopolamine as a ‘Cognitive Stress Test’: Rationale and Test of a Very Low Dose in an At-Risk Cohort of Older Adults. Alzheimers Dement 10 (2014), 262–267.
28. [28] Maruff, P., Lim, Y.Y., Darby, D., Ellis, K.A., Pietrzak, R.H., Snyder, P.J., et al. Clinical utility of the Cogstate Brief Battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. BMC Psychol 1 (2013), 1–11.
29. [29] Snyder, P., Bednar, M.M., Cromer, J.R., Maruff, P., Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement 1 (2005), 126–135.
30. [30] Fredrickson, A., Snyder, P.J., Cromer, J., Thomas, E., Lewis, M., Maruff, P., The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: An example with scopolamine. Hum Psychopharmacol 23 (2008), 425–436.
31. [31] Lim, Y.Y., Prang, K.H., Cysique, L., Pietrzak, R., Snyder, P.J., Maruff, P., A method for cross-cultural adaptation of a verbal memory assessment. Behav Res Methods 41 (2009), 1190–1200.
32. [32] Clark, C.M., Schneider, J.A., Bedell, B.B., Beach, T.G., Bilker, W.B., Mintun, M.A., et al. Use of Florbetapir-PET for imaging amyloid-β pathology. JAMA 305 (2011), 275–283.
33. [33] Johnson, L.V., Leitner, W.P., Rivest, A.J., Staples, M.K., Radeke, M.J., Anderson, D.H., The Alzheimer's Aβ peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A 99 (2002), 11830–11835.
34. [34] Jack, C.R., Wiste, H.J., Lesnick, T.G., Weigand, S.P., Knopman, D.S., Vemuri, P., et al. Brain β-amyloid load approaches a plateau. Neurology 80 (2013), 1–7.
35. [35] Region Finder Use Manual. Software Version 2.4. 2011, Heidelberg Engineering GmBH, Carlsbad, CA.
36. [36] Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57 (1995), 289–300.
37. [37] Frost, S., Kanagsingam, Y., Sohrabi, H., Vignarajan, J., Bourgeat, P., Salvado, O., et al. Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. Transl Psychiatry, 3, 2013, e233.
38. [38] Koronyo-Hamaoui, M., Koronyo, Y., Ljubimov, A., Miller, C.L., Ko, M.K., Black, K.L., et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 54 (2011), S204–S217.
39. [39] Goldstein, L.E., Muffat, J.A., Cherny, R.A., Moir, R.D., Ericsson, M.H., Huang, X., et al. Cystolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet Neurol 361 (2003), 1258–1265.
40. [40] Koronyo, Y., Salumbides, B., Black, K., Koronyo-Hamaoui, M., Alzheimer's disease in the retina: Imaging retinal Aβ plaques for early diagnosis and therapy treatment. Neurodegener Dis 10 (2012), 285–293.
41. [41] Kayabasi, U., Sergott, R., Rispoli, M., Retinal examination for the diagnosis of Alzheimer's disease. Int J Ophthamalic Pathol 3 (2014), 4–7.
42. [42] Ho, C.Y., Troncoso, J.C., Knox, D., Stark, W., Eberhart, C.G., Beta-amyloid, phospho-tau, and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients. Brain Pathol 24 (2014), 25–32.
43. [43] Schon, C., Hoffman, N.A., Ochs, S.M., Burgold, S., Filser, S., Steinbach, S., et al. Long-term in-vivo imaging of fibrillary tau in the retina of P310S transgenic mice. PLoS One, 7, 2012, e53547.
44. [44] Masland, R.H., Mills, J.W., Autoradiographic identification of acetylcholine in the rabbit retina. J Cell Biol 83 (1979), 159–178.
45. [45] Massey, S.C., Neal, M.J., The light evoked release of acetylcholine from the rabbit retina in vivo and it's inhibition by γ-aminobutyric acid. J Neurochem 32 (1979), 1327–1329.
46. [46] Pombal, M., Abalo, X., Rodicio, M., Anadon, R., Gonzalez, A., Choline acetyltransferase-immunoreactive neurons in the retina of adult and developing lampreys. Brain Res 993 (2003), 154–163.
47. [47] Lopez, J., Moreno, N., Gonzalez, A., Localization of choline acetyltransferase in the developing and adult retina of Xenopus laevis. Neurosci Lett 330 (2002), 61–64.
48. [48] Ivanova, E., Toychiev, A., Yee, C., Sagdullaev, B., Intersublaminar vascular plexus: The correlation of retinal blood vessels with functional sublaminae of the inner plexiform layer. Invest Ophthamol Vis Sci 55 (2014), 78–86.
49. [49] Zarbin, M., Wamsley, J., Palacios, J., Kuhar, M., Autoradiographic localization of high affinity GABA, benzodiazepine, dopaminergic, adrenergic, and muscarinic cholinergic receptors in the rat, monkey, and human retina. Brain Res 374 (1986), 75–92.
50. [50] Bowen, D.M., Benton, J.S., Spillane, J.A., Smith, C.C.T., Allen, S.J., Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci 57 (1982), 191–202.
51. [51] Pike, K.E., Savage, G., Villemagne, V.L., Ng, S., Moss, S.A., Maruff, P., et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130 (2007), 2837–2844.
52. [52] Reiman, E.M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106 (2009), 6820–6825.
53. [53] Beach, T.G., Kuo, Y.M., Spiegel, K., Emmerling, M.R., Sue, L.I., Kokjohn, K., et al. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer's disease. J Neuropathol Exp Neurol 59 (2000), 308–313.
54. [54] Beach, T.G., Walker, D., Sue, L., Scott, S., Layne, K.J., Newell, A.J., et al. Immunotoxin lesion of the cholinergic nucleus basalis causes Aβ deposition: Towards a physiologic animal model of Alzheimer's disease. Curr Med Chem 3 (2003), 57–75.
55. [55] Davis, A.A., Fritz, J.J., Wess, J., Lah, J.J., Levey, A.I., Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J Neurosci 30 (2010), 4190–4196.
56. [56] Seo, H., Ferree, A.W., Isacson, O., Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice. Eur J Neurosci 15 (2002), 498–506.
57. [57] Potter, P.E., Rauschkolb, P.K., Pandya, Y., Sue, L.I., Sabbagh, M.N., Walker, D.G., et al. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol 122 (2011), 49–60.